opc 12759 has been researched along with Parkinsonian Disorders in 1 studies
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mishra, A | 1 |
| Krishnamurthy, S | 1 |
1 other study available for opc 12759 and Parkinsonian Disorders
| Article | Year |
|---|---|
Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats.
Topics: Administration, Oral; Alanine; alpha-Synuclein; Animals; Antioxidants; Antiparkinson Agents; Apoptos | 2019 |